Kendrick Charles Morgan JR

EVP & President (Commercial) Kendrick Charles Morgan JR sold 3,196 shares of ELV at $284.92 on 2026-03-06; stock down -38.0% from 52-week high.

Kendrick Charles Morgan JR, EVP & President (Commercial) at Elevance Health, sold 3,196 shares for $910,604.32, reducing his holdings by 21.3%. The sale occurred at $284.92 per share; the stock has since fallen to $280.74 and is trading -38.0% below its 52-week high of $452.69, with a -17.2% decline over the prior 30 days. Notably, at this same ticker, his prior three sales showed mixed timing outcomes: the 2025-03-05 and 2024-03-08 sales were followed by positive 30-day returns, while the 2024-10-18 sale was followed by negative returns at both 30- and 90-day windows, with 2 of 3 prior ELV sales well-timed at the 90-day mark. His cross-ticker track record shows 3 prior sells with a 66.67% well-timed rate at 90 days, though the average 90-day return was -2.4%. The company's fundamentals remain solid—$50.7B in latest quarterly revenue, $1.2B net income, +12.5% annual revenue growth, and an 11.88 P/E ratio—warranting examination of whether the sale reflects portfolio management amid the recent sharp equity decline or other factors.

EVP & President Morgan sells 3,504 ELV shares at $396.30; stock -29.3% from 52-week high

Kendrick Charles Morgan JR, EVP & President of Commercial at Elevance Health, sold 3,504 shares (3.5K shares) for $1,388,635.20 on 2025-03-05, reducing his holdings by -25.7% from 13,620 to 10,116 shares. The sale occurred at $396.30, while the stock now trades at $397.47 and is -29.3% from its 52-week high of $562.29, indicating material weakness in ELV's valuation since peak. His prior two sales at ELV (2024-10-18 and 2024-03-08) showed mixed outcomes: the October 2024 sale was followed by a -10.8% 90-day decline (well-timed), while the March 2024 sale saw a +8.1% 90-day gain (poorly timed); across all tickers, his 50.00% well-timed rate on sells does not indicate a strong pattern of prescience. The company's fundamentals remain solid (P/E 14.09, $45.1B revenue, +3.3% annual growth, $1.0B net income), but the sale's scale—representing a meaningful reduction in his direct equity stake—warrants observation for any shift in his conviction at a company where he holds a senior operational role.

EVP & President Kendrick Morgan sold 7,417 ELV shares at $432.14 on 2024-10-18, retaining 8,423 shares post-transaction.

Kendrick Charles Morgan JR, EVP & President of Commercial at Elevance Health, executed a sale of 7,417 shares valued at $3,205,182.38, reducing his holdings by -46.8% to 8,423 shares. The transaction occurred at $432.14, and the stock has since declined -20.2% over the past 30 days and -23.4% from its 52-week high of $562.29. His prior sell at ELV on 2024-03-08 generated positive 90-day returns (+8.1%), indicating the earlier sale preceded a rise in stock price—a poorly timed outcome for capturing downside. The current sale occurs in a context of significant recent weakness, yet the insider's historical track record at this ticker shows no pattern of well-timed sells (0 of 1 prior sells were well-timed at the 90-day mark). The company's fundamentals remain stable with $45.1B revenue, +9.4% annual growth, and a P/E of 15.57, offering limited fundamental justification for the magnitude of recent price deterioration.